KODAK LIMITED

Financial Health Assessment: KODAK LIMITED

1. Financial Health Score: B+ (Stable & Well-Supported) This score reflects a patient with a very strong constitutional structure and an excellent support system. The company displays no external symptoms of distress—filings are healthy and on time, and the corporate governance structure is robust. However, without the full "blood work" (detailed profit & loss and cash flow statements), we cannot confirm peak operational vitality, hence the score sits at a strong B+ rather than a perfect A+. The massive share capital acts as a tremendous financial reserve, ensuring the patient is highly resilient to sudden economic shocks.

2. Key Vital Signs * Pulse (Corporate Status & Age): Active & Enduring. Incorporated in 1898, this is a patient with over 125 years of history. The pulse is steady; the company is active and not in liquidation or administration, indicating long-term survival instincts and adaptability. * Blood Pressure (Share Capital): Extremely Robust. The share capital is listed at £130,000,010. This is a massive capital base, acting as thick arterial walls that prevent sudden collapse. It shows that the company has been heavily capitalized, providing a substantial buffer against liabilities. * Nervous System (Governance & Control): Centralized & High-Functioning. Eastman Kodak Company holds over 75% of shares, voting rights, and director appointment powers. The nervous system is highly centralized, meaning strategic impulses come from a global parent. The officer list includes senior global executives (e.g., Senior Vice President, General Manager WW Sales), indicating this entity is a critical, functioning organ within a larger global body, not a dormant limb. * Immune System (Filing Compliance): Strong. The company files full accounts (expected for an entity of this size) and is entirely up to date with both annual accounts and confirmation statements. There are no signs of regulatory infection or penalty-induced stress. * Organ Function (Business Activity): Evolving. The SIC code points to "Other publishing activities," while the website describes a global technology company focused on commercial print, packaging, and manufacturing. This is a minor discrepancy suggesting the Companies House classification hasn't been updated to perfectly reflect the current operational reality of the business.

3. Diagnosis Based on the available indicators, KODAK LIMITED is in excellent structural health. It shows no symptoms of financial distress—no overdue filings, no history of insolvency, and no disqualifications among the directors. The company operates as a wholly-owned subsidiary of the iconic Eastman Kodak Company, which provides a strong "parental" life-support system. If this entity experiences a localized cash flow fever, the global parent has the authority and likely the financial incentive to provide necessary transfusions.

The primary observation is that the detailed profitability and working capital metrics (the "blood work") are not visible in this top-level scan. However, the sheer size of the share capital and the presence of global senior leadership strongly suggest this is a strategically important, well-funded entity rather than a shell or a distressed business. The only minor "ache" is the slight mismatch between the registered business activity and the actual stated business activity, which is a common administrative lag but could cause slight confusion for external observers.

4. Recommendations * Update the Administrative Diet: Update the SIC code to accurately reflect the current technological and manufacturing activities rather than just "publishing." This ensures external diagnosticians have an accurate baseline reading of what the company actually does. * Monitor the Parent's Health: Because the company's nervous system is entirely controlled by Eastman Kodak Company, any systemic illness or financial fever in the US parent will inevitably flow downstream. Regular monitoring of the parent company's global financial health is essential for predicting local impacts. * Review the Full Blood Work: Once the detailed accounts (made up to December 31, 2024) are fully processed, conduct a deep dive into the working capital (Current Assets vs. Current Liabilities) and retained profits (P&L Reserve). This will confirm whether the day-to-day cash flow is self-sustaining or if it relies on regular capital injections from the parent. * Maintain Preventative Compliance: Continue the current excellent regimen of timely filings to avoid unnecessary regulatory penalties and maintain a clean public record.